Trial Profile
A Phase 1, Open Label, Single-Dose, Within Cohort Randomized, 2-Way Crossover Study To Evaluate The Pharmacokinetics Of A Modified Release Formulation Of Pf-06650833 Under Fasting And Fed Conditions In Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Zimlovisertib (Primary)
- Indications Hidradenitis suppurativa; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 07 Mar 2016 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov record.
- 25 Nov 2015 New trial record